Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 1699 (LINC01699), also known as GM140, is a human long non-coding RNA (lncRNA)[1][3][5][9]. It does not code for a protein and belongs to the class of lncRNAs, which are RNA molecules longer than 200 nucleotides that generally do not get translated into protein but may have regulatory functions in gene expression[3][5]. There is little to no published evidence that LINC01699 acts as a direct therapeutic target, or that it is involved in well-characterized signaling pathways, diseases, or recognized as a clinical biomarker. As of now, its biological functions, disease associations, and relevance as a therapeutic target remain largely uncharacterized in the literature and biological databases[1][3][5][7][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 1699 (LINC01699).